A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513919-27-00

Acronym

GS-US-417-0304

Enrollment

254

Registered

2024-07-11

Start date

2017-09-14

Completion date

2025-04-15

Last updated

2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Brief summary

Safety, evaluated through AEs, clinical laboratory tests, and vital signs.

Detailed description

ACR-N responses in each arm.

Interventions

DRUGJyseleca 100 mg film-coated tablets

DRUGJyseleca 200 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety, evaluated through AEs, clinical laboratory tests, and vital signs.	—

Secondary

Measure	Time frame
ACR-N responses in each arm.	—

Countries

Bulgaria, Germany, Hungary

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026